-
Je něco špatně v tomto záznamu ?
Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a)
D. Dlouha, I. Prochazkova, Z. Eretova, JA. Hubacek, A. Parikova, J. Pitha,
Jazyk angličtina Země Nizozemsko
Typ dokumentu kazuistiky, časopisecké články
Grantová podpora
NV17-28882A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Elsevier Open Access Journals
od 2019-12-01 do 2019
- MeSH
- biologické markery krev MeSH
- cirkulující mikroRNA krev MeSH
- hyperlipoproteinemie krev komplikace terapie MeSH
- lidé MeSH
- lipoprotein (a) krev MeSH
- nemoci koronárních tepen krev komplikace terapie MeSH
- senioři MeSH
- separace krevních složek * MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
BACKGROUND: Lipoprotein apheresis (LA) is a well-established therapy for lowering lipid levels in serious cases of dyslipidaemia, including high levels of lipoprotein(a) [Lp(a)]. This method lowers both LDL cholesterol and Lp(a) by more than 60% in most of patients; however, because randomized clinical studies could be extremely difficult, also other markers of the effect of this procedures on vascular health are of importance. Therefore, in addition to changes in plasma lipids and Lp(a) during LA, we also analysed the response of biomarkers associated with vascular integrity: small non-coding microRNAs (miRNAs). MATERIALS AND METHODS: We analysed the changes in miRNAs in two women (age 70 and 72 years) with clinically manifest extensive and progressive atherosclerotic disease and high levels of Lp(a) and with different clinical course who were treated by LA. In both women we analysed changes of 175 circulating plasma miRNAs using pre-defined serum/plasma focus panels at the beginning of and one year after the therapy. RESULTS: In addition to reduced levels of plasma lipids and Lp(a), circulating plasma levels of miR-193a-5p; -215-5p; -328-3p; -130a-3p; -362-3p; -92b-3p decreased, and levels of miR-125a-5p; -185-5p; -106a-5p; -320b; -19a increased (all P < 0.05) in both women. Moderate differences were found between both women with regard to the different course of atherosclerotic disease. CONCLUSIONS: Long-term LA substantially changes circulating plasma miRNAs associated with vascular integrity reflected different clinical course in both women. If confirmed, this approach could improve the assessment of the effectiveness of this therapy on an individual basis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023369
- 003
- CZ-PrNML
- 005
- 20201214125850.0
- 007
- ta
- 008
- 201125s2019 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.atherosclerosissup.2019.08.036 $2 doi
- 035 __
- $a (PubMed)31818442
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Dlouha, Dana $u Centre for Experimental Medicine - Laboratory for Atherosclerosis Research, Institute for Clinical and Experimental Medicine, Czech Republic. Electronic address: dadl@ikem.cz.
- 245 10
- $a Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a) / $c D. Dlouha, I. Prochazkova, Z. Eretova, JA. Hubacek, A. Parikova, J. Pitha,
- 520 9_
- $a BACKGROUND: Lipoprotein apheresis (LA) is a well-established therapy for lowering lipid levels in serious cases of dyslipidaemia, including high levels of lipoprotein(a) [Lp(a)]. This method lowers both LDL cholesterol and Lp(a) by more than 60% in most of patients; however, because randomized clinical studies could be extremely difficult, also other markers of the effect of this procedures on vascular health are of importance. Therefore, in addition to changes in plasma lipids and Lp(a) during LA, we also analysed the response of biomarkers associated with vascular integrity: small non-coding microRNAs (miRNAs). MATERIALS AND METHODS: We analysed the changes in miRNAs in two women (age 70 and 72 years) with clinically manifest extensive and progressive atherosclerotic disease and high levels of Lp(a) and with different clinical course who were treated by LA. In both women we analysed changes of 175 circulating plasma miRNAs using pre-defined serum/plasma focus panels at the beginning of and one year after the therapy. RESULTS: In addition to reduced levels of plasma lipids and Lp(a), circulating plasma levels of miR-193a-5p; -215-5p; -328-3p; -130a-3p; -362-3p; -92b-3p decreased, and levels of miR-125a-5p; -185-5p; -106a-5p; -320b; -19a increased (all P < 0.05) in both women. Moderate differences were found between both women with regard to the different course of atherosclerotic disease. CONCLUSIONS: Long-term LA substantially changes circulating plasma miRNAs associated with vascular integrity reflected different clinical course in both women. If confirmed, this approach could improve the assessment of the effectiveness of this therapy on an individual basis.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 12
- $a separace krevních složek $7 D001781
- 650 _2
- $a cirkulující mikroRNA $x krev $7 D000074166
- 650 _2
- $a nemoci koronárních tepen $x krev $x komplikace $x terapie $7 D003324
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperlipoproteinemie $x krev $x komplikace $x terapie $7 D006951
- 650 _2
- $a lipoprotein (a) $x krev $7 D017270
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Prochazkova, Iveta $u Centre for Experimental Medicine - Laboratory for Atherosclerosis Research, Institute for Clinical and Experimental Medicine, Czech Republic.
- 700 1_
- $a Eretova, Zuzana $u Clinic of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Czech Republic.
- 700 1_
- $a Hubacek, Jaroslav A $u Centre for Experimental Medicine - Laboratory for Atherosclerosis Research, Institute for Clinical and Experimental Medicine, Czech Republic.
- 700 1_
- $a Parikova, Alena $u Clinic of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Czech Republic.
- 700 1_
- $a Pitha, Jan $u Centre for Experimental Medicine - Laboratory for Atherosclerosis Research, Institute for Clinical and Experimental Medicine, Czech Republic; Department of Internal Medicine, 2nd Medical Faculty, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00006853 $t Atherosclerosis. Supplements $x 1878-5050 $g Roč. 40, č. - (2019), s. 12-16
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31818442 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125849 $b ABA008
- 999 __
- $a ok $b bmc $g 1595688 $s 1114045
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 40 $c - $d 12-16 $e - $i 1878-5050 $m Atherosclerosis supplements $n Atheroscler Suppl $x MED00006853
- GRA __
- $a NV17-28882A $p MZ0
- LZP __
- $a Pubmed-20201125
